To switch (statins) or not to switch? That is the question

Author： Athyros Vasilios G Tziomalos Konstantinos Karagiannis Asterios Mikhailidis Dimitri P

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.18, 2010-12, pp. : 2943-2946

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A pharmacy discount card programme encouraging elderly patients receiving higher-priced, brandname statins to switch to Andrx's extended-release lovastatin [`Altocor'] is due to be launched

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 406, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Abciximab to tirofiban switch not worth it

Inpharma, Vol. 1, Iss. 1412, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Tedisamil: master switch of nature?

By Doggrell S.A.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 1, 2001-01 ,pp. : 129-138

Informa Healthcare

Access to resources Recommend Favorite

Switch to lansoprazole: failure not more costly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 326, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Piribedil hits the `on' switch in PD patients

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite